The short version
Only one company currently supplies this market — there is no backup if it stumbles.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Phesgo
pertuzumab, trastuzumab, and hyaluronidase-zzxf · PERTUZUMAB 600 mg/10mL; TRASTUZUMAB 600 mg/10mL; HYALURONIDASE (HUMAN RECOMBINANT) 20000 U/10mL · Injection, Solution · Subcutaneous · Genentech, Inc.
NDC 50242-0260-01 · 1 VIAL, SINGLE-DOSE in 1 CARTON / 10 mL in 1 VIAL, SINGLE-DOSE · BLA · View full market →
One drug, every price
The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.
ⓘ How this was built
Data sources
- CMS NADAC (pharmacy acquisition, weekly)
- CMS Part B ASP quarterly payment limits
- CMS Maximum Fair Prices (IRA negotiated, NDC-level)
- Medicare Part D Spending by Drug (data.cms.gov, name-matched)
- VA FSS / Big4 federal contract prices (va.gov, twice monthly)
- ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
- California SB-17 WAC filings (list price, per package)
Method
Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
- Medicare Part B pays (ASP+6%)$59.90per billing unit (10 MG)HCPCS J9316 · Jul 1, 2026
- Part D plans paid (avg)$855.98per dosage unitgross, before rebates — matched by drug name · 2024
- Federal ceiling (Big4)$5,871.37per package of 10MLGenentech USA, Inc. · Jan 1, 2026
Medicare Part D
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Estimated fill cost
WAC per package, as filed
$9,694.80
Reported to Texas DSHS · 2026 annual filing · Genentech USA, Inc.
Manufacturer list price as filed — not what pharmacies actually pay after discounts.
Medicare Part B (ASP)
Payment limit per 10 MG
$59.895
HCPCS J9316 · Jul 1, 2026 quarter · typically ASP + 6%
Medicaid spend (2025)
$45.1M
6,661 prescriptions paid by Medicaid nationally · all Medicaid spend →
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
Where it's made
- F. Hoffmann-La Roche AGSwitzerlandanalysis · label · manufacture · pack
- Genentech, Inc.United Statesanalysis
- Genentech, Inc.United Statesanalysis · api manufacture
- Roche Diagnostics GmbHGermanyanalysis · manufacture
- Roche Diagnostics GmbHGermanyanalysis · api manufacture
- analysis · api manufacture
Establishments this product's FDA label declares, located via FDA registration data. How we built this →
Is this a "specialty" drug?
There's no legal definition — it meets 3 of 6 public criteria. Why that matters →
- Part D specialty tier
- Costs ≥ $950/fill · avg $8,808.49 per prescription
- Biologic (BLA)
- Injectable / infused
- Orphan-drug exclusivity
- REMS program
Regulatory
- Application
- BLA761170
- TE code
- —
- Approval date
- —
- Patents / exclusivity
- None on file
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of pertuzumab, trastuzumab, and hyaluronidase-zzxf (Injection, Solution)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Genentech, Inc. | PERTUZUMAB 1200 mg/15mL; TRASTUZUMAB 600 mg/15mL; HYALURONIDASE (HUMAN RECOMBINANT) 30000 U/15mL | Aug 26, 2026 | Sep 2, 2026 |
| Genentech, Inc. | PERTUZUMAB 600 mg/10mL; TRASTUZUMAB 600 mg/10mL; HYALURONIDASE (HUMAN RECOMBINANT) 20000 U/10mL | Aug 26, 2026 | Sep 2, 2026 |
| Genentech, Inc. | PERTUZUMAB 20000 U/10mL; TRASTUZUMAB 600 mg/10mL; HYALURONIDASE (HUMAN RECOMBINANT) 600 mg/10mL | Jul 22, 2026 | Aug 19, 2026 |
| Genentech, Inc. | PERTUZUMAB 30000 U/15mL; TRASTUZUMAB 1200 mg/15mL; HYALURONIDASE (HUMAN RECOMBINANT) 600 mg/15mL | Jul 22, 2026 | Aug 19, 2026 |
| Genentech, Inc. | HYALURONIDASE (HUMAN RECOMBINANT) 20000 U/10mL; PERTUZUMAB 600 mg/10mL; TRASTUZUMAB 600 mg/10mL | Jul 15, 2026 | Jul 15, 2026 |
| Genentech, Inc. | HYALURONIDASE (HUMAN RECOMBINANT) 30000 U/15mL; PERTUZUMAB 1200 mg/15mL; TRASTUZUMAB 600 mg/15mL | Jul 15, 2026 | Jul 15, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Phesgo — NDC 50242-0260-01," retrieved September 3, 2026, https://drugdashboards.com/drug/50242026001.
Free to cite with attribution — see how the data is put together.